Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 196 Myelodysplastic Syndromes 128 Precursor Cell Lymphoblastic Leukemia-Lymphoma 123 Leukemia, Lymphocytic, Chronic, B-Cell 102 Leukemia 102 Lymphoma 86 Multiple Myeloma 81 Lymphoma, Non-Hodgkin 80 Hematologic Neoplasms 65 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 62 Hodgkin Disease 62 Recurrence 52 Lymphoma, B-Cell 40 Lymphoma, Mantle-Cell 39 Myeloproliferative Disorders 36 Lymphoma, Follicular 35 Melanoma 34 Lymphoma, Large B-Cell, Diffuse 31 Burkitt Lymphoma 31 Graft vs Host Disease 28 Neoplasms, Plasma Cell 24 Primary Myelofibrosis 23 Ovarian Neoplasms 23 Lymphoma, B-Cell, Marginal Zone 23 Anemia, Refractory, with Excess of Blasts 21 Leukemia, Myelomonocytic, Chronic 20 Leukemia, Biphenotypic, Acute 17 Lymphoma, T-Cell 16 Neuroblastoma 15 Neoplasms 14

Interventions

Granulocyte-Macrophage Colony-Stimulating Factor 2 Colony-Stimulating Factors 2 nabiximols 1 fludarabine 1 camrelizumab 1 Radiofrequency Ablation 1 Interleukin-2 1 Immune Checkpoint Inhibitors 1 Cyclophosphamide 1 Adjuvants, Immunologic 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Advanced Malignant Solid Tumor × fludarabine × Clear all

NCT03171220 2017-06-06

NRT-01

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 1/2 Unknown

Other solid neoplasm

Advanced Malignant Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡